A Bayesian cost-benefit approach to the determination of sample size in clinical trials

Statistics in Medicine

Volumn 27, Issue 1, 2008, Pages 68-82

  Kikuchi, Takashi ^a   Pezeshk, Hamid ^b   Gittins, John ^c  

^a BANGOR UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF TEHRAN   (Iran)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bayesian; Clinical trials; Cost benefit; Monte Carlo simulation; Sample size

Indexed keywords

NEW DRUG;

ANALYSIS OF VARIANCE; ARTICLE; BAYES THEOREM; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; EFFECT SIZE; HUMAN; INTERMETHOD COMPARISON; MONTE CARLO METHOD; OUTCOME ASSESSMENT; SAMPLE SIZE; SAMPLING ERROR; SENSITIVITY ANALYSIS;

ANALYSIS OF VARIANCE; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; MONTE CARLO METHOD; SAMPLE SIZE;

EID: 38849173686     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2965     Document Type: Article

References (24)

1. Desu MM, Raghavarao D. Sample Size Methodology. Academic Press: New York, 1990.
2. Lemeshow S, Homser Jr DW, Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. Wiley: New York, 1990.
3. Lindley DV. The choice of sample size. The Statistician 1997; 46:129-138.
4. van Gijn J. Low doses of aspirin in stroke prevention. The Lancet 1999; x46(9171):2172-2173.
5. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MGM, Goldman L. Cost effectiveness of Aspirin, Clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine 2002; 346(23):1800-1806.
6. Spiegelhalter DJ, Freedman LS. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Statistics in Medicine 1986; 5:1-13.
7. Hutton JL, Owens RG. Bayesian sample size calculation and prior beliefs about child sexual abuse. The Statistician 1993; 42:399-404.
8. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Economics 1996; 5:513-524.
9. Joseph L, Duberger R, Belisle P. Bayesian and mixed Bayesian likelihood criteria for sample size determination. Statistics in Medicine 1997; 16:769-781.
10. Lee SJ, Zelen M. Clinical trials and sample size considerations: another perspective. Statistical Science 2000; 15:95-103.
11. O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Medical Decision Making 2001; 21:219-230.
12. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley: New York, 2003.
13. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Statistics in Medicine 2002; 21: 1991-2012.
14. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10(1):1-10.
15. Gajewski BJ, Mayo MS. Bayesian sample size calculation in phase II clinical trials using a mixture of informative priors. Statistics in Medicine 2007, in press.
16. O'Hagan A, Stevens, JW, Bayesian assessment of sample size for clinical trials of cost effectiveness. Medical Decision Making 1991; 21:219-230.
17. Department of Health and Aging, Australian Government. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee; Including Submissions Involving Economic Analysis. Department of Health and Aging, Australian Government. http://www.health.gov.au/internet/wcms/ publishing.nsf/content/health-pbs-general-pubs-guidelines-content.htm, 2005.
18. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals (2nd edn). Canadian Coordinating Office for Health Technology Assessment. www.farmacoeconomia.com/Directrices/canada.pdf [November 1997].
19. Norwegian Medicines Agency (Statetns Legemiddelverk). Norwegian Guidelines for Pharmacoeconomic Analysis in Connection with Applications for Reimbursement. Norwegian Medicines Agency (Statetns Legemiddelverk) http://www.legemiddelverket.no/eng/reg/ pharmacoeconomic-analysis-guidelines.htm [15 November 2004].
20. National Institute for Clinical Excellence. The Institute's Interim Guidance to Manufacturers and Sponsors. National Institute for Clinical Excellence. http://www.nice.org.uk/pdf/4TAP_Methods.pdf [10 October 2004].
21. Gittins JC, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34:355-363.
22. Gittins JC, Pezeshk H. How large should a clinical trial be? The Statistician 2000; 49(2):177-187.
23. O'Hagan A. Kendall's Advanced Theory of Statistics: Bayesian Inference. Arnold: Paris, 1994.
24. Dobson AJ. Calculating sample size. Transactions of Menzies Foundation 1984; 7:75-79.